# Off-the-shelf NK Cells + SCT for Myeloid Malignancies

> **NCT05115630** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Myeloid Malignancies
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **DRUG:** Filgrastim
- **DRUG:** Melphalan
- **DRUG:** Fludarabine phosphate
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Total Body Irradiation One Dose

## Key facts

- **NCT ID:** NCT05115630
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-08
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-05-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05115630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05115630, "Off-the-shelf NK Cells + SCT for Myeloid Malignancies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05115630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*